1
|
Khan MM, Yalamarty SSK, Rajmalani BA, Filipczak N, Torchilin VP. Recent strategies to overcome breast cancer resistance. Crit Rev Oncol Hematol 2024; 197:104351. [PMID: 38615873 DOI: 10.1016/j.critrevonc.2024.104351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Revised: 01/24/2024] [Accepted: 04/10/2024] [Indexed: 04/16/2024] Open
Abstract
Breast cancer is potentially a lethal disease and a leading cause of death in women. Chemotherapy and radiotherapy are the most frequently used treatment options. Drug resistance in advanced breast cancer limits the therapeutic output of treatment. The leading cause of resistance in breast cancer is endocrine and hormonal imbalance, particularly in triple negative and HER2 positive breast cancers. The efflux of drugs due to p-gp's activity is another leading cause of resistance. Breast cancer resistant protein also contributes significantly. Strategies used to combat resistance include the use of nanoparticles to target drug delivery by co-delivery of chemotherapeutic drugs and genes (siRNA and miRNA) that help to down-regulate genes causing resistance. The siRNA is specific and effectively silences p-gp and other proteins causing resistance. The use of chemosensitizers is also effective in overcoming resistance. Chemo-sensitizers sensitize cancer cells to the effects of chemotherapeutic drugs. Novel anti-neoplastic agents such as antibody-drug conjugates and mesenchymal stem cells are also effective tools used to improve the therapeutic response in breast cancer. Similarly, combination of photo/thermal ablation with chemotherapy can act to overcome breast cancer resistance. In this review, we focus on the mechanism of breast cancer resistance and the nanoparticle-based strategies used to combat resistance in breast cancer.
Collapse
Affiliation(s)
- Muhammad Muzamil Khan
- Center of Nanomedicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | | | - Bharat Ashok Rajmalani
- Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA
| | - Nina Filipczak
- Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA
| | - Vladimir P Torchilin
- Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA; Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA.
| |
Collapse
|
2
|
Yin X, Wu B, Yang Y, Shi J, Fu Y, Zhang H, Ye J, Sun Y, Chen C, Zhu Y, Zhang W. Precision targeting of CuET overload to disrupt mitochondrial unfolded protein response by integrated liposome. Int J Biol Macromol 2024; 262:129974. [PMID: 38331068 DOI: 10.1016/j.ijbiomac.2024.129974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2023] [Revised: 01/29/2024] [Accepted: 02/02/2024] [Indexed: 02/10/2024]
Abstract
Mitochondria in breast cancer play a critical role in survival and adaptation to dynamic environments. Thus, targeting mitochondria emerges as a promising therapeutic strategy for breast cancer. However, the adaptive unfolded protein response in mitochondria (UPRmt) due to mitochondrial unspecific distribution might contribute to diminished therapeutic outcomes. Herein, mitochondrial targeting liposome agents (CTPP-Lipid) are constructed and adopted for delivering the copper ion (CuET-DSF), which is especially sensitive for mitochondria-abundant breast tumors. In brief, the CTPP-Lipid@CuET achieves the goal of Cu2+ overloading by mitochondria targeting delivery. This rapidly increases ROS production, disrupts mitochondrial structure, and avoids the adaptive UPRmt formation, finally leading to apoptosis of breast cancer cells. In general, the Cu2+ overloading at mitochondria by CTPP-Lipid@CuET is a potential strategy for antitumor therapy, providing new insights into breast tumor therapy.
Collapse
Affiliation(s)
- Xi Yin
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China; Division of Breast Surgery, Department of General Surgery, The Second Affiliated Hospital of Xiamen Medical College, Xiamen 361000, China
| | - Baojuan Wu
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China
| | - Yaxuan Yang
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China
| | - Jiajun Shi
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China
| | - Yuping Fu
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China; Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210000, China
| | - Hongmei Zhang
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China; Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210000, China
| | - Jiahui Ye
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China
| | - Yuxiang Sun
- Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou 225001, China
| | - Changrong Chen
- Department of Emergency Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210000, China.
| | - Yun Zhu
- Department of Pharmacy, Nanjing Drum Tower Hospital, Drum Tower Clinical Medical College of Nanjing Medical University, Nanjing 210008, China; Nanjing Medical Center for Clinical Pharmacy, Nanjing 210008, China.
| | - Weijie Zhang
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.
| |
Collapse
|
3
|
Pan C, Cong A, Ni Q. Microarray data reveal potential genes that regulate triple-negative breast cancer. J Int Med Res 2022; 50:3000605221130188. [PMID: 36238993 PMCID: PMC9575453 DOI: 10.1177/03000605221130188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
Objective Triple-negative breast cancer (TNBC) is characterized by a lack of targeted
therapies and poor patient prognosis, and its underlying pathological
mechanisms remain unclear. This study aimed to identify potential key genes
and related pathways that are required for TNBC development. Methods We screened the Gene Expression Omnibus database for transcriptome data and
identified differently expressed genes in TNBC. Then, we performed Gene
Ontology analysis to determine the genes and pathways involved in TNBC
development. We correlated significantly expressed genes and miRNAs using
miRDB, TargetScan, miRWalk, and DIANA, and then validated the expression of
CDK1 and miR-143-3p in TNBC patients. Results Eighteen genes were significantly upregulated in TNBC patients, and these
were found to be enriched in cell metabolic process, cell division,
mitochondrion, and respiratory chain. MiR-143-3p was found to be an upstream
regulator of CDK1. Validation experiments revealed that CDK1 was upregulated
while miR-143-3p was downregulated in clinical TNBC specimens. Conclusions Collectively, our results revealed 18 upregulated genes in TNBC. Notably,
CDK1 and its related microRNA miR-143-3p could be potential therapeutic
targets for TNBC.
Collapse
Affiliation(s)
- Chi Pan
- Department of General Surgery, Jiangsu Taizhou People’s
Hospital, Taizhou, China
| | - Aihua Cong
- Department of Oncology, Jiangsu Taizhou People’s Hospital,
Taizhou, China
| | - Qingtao Ni
- Department of Oncology, Jiangsu Taizhou People’s Hospital,
Taizhou, China,Qingtao Ni, Department of Oncology, Jiangsu
Taizhou People’s Hospital, Hailing South Road 399, Taizhou 225300, China.
| |
Collapse
|
4
|
Acconcia F. Editorial for the Special Issue “New Drugs for Breast Cancer Treatment”. Int J Mol Sci 2022; 23:ijms231810265. [PMID: 36142174 PMCID: PMC9499552 DOI: 10.3390/ijms231810265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2022] [Accepted: 09/05/2022] [Indexed: 11/16/2022] Open
Affiliation(s)
- Filippo Acconcia
- Department of Sciences, University Roma Tre, Viale Guglielmo Marconi, 446, I-00146 Rome, Italy
| |
Collapse
|
5
|
Isbera M, Bognár B, Gallyas F, Bényei A, Jekő J, Kálai T. Syntheses and study of a pyrroline nitroxide condensed phospholene oxide and a pyrroline nitroxide with diphenylphosphino moiety. PHOSPHORUS SULFUR 2022. [DOI: 10.1080/10426507.2021.1989690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Mostafa Isbera
- Faculty of Pharmacy, Institute of Organic and Medicinal Chemistry, University of Pécs, Pécs, Hungary
| | - Balázs Bognár
- Faculty of Pharmacy, Institute of Organic and Medicinal Chemistry, University of Pécs, Pécs, Hungary
| | - Ferenc Gallyas
- Department of Biochemistry and Medical Chemistry, University of Pécs Medical School, Pécs, Hungary
- HAS-UP Nuclear-Mitochondrial Interactions Research Group, Budapest, Hungary
- János Szentágothai Research Center, University of Pécs, Pécs, Hungary
| | - Attila Bényei
- Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Hungary
| | - József Jekő
- Department of Chemistry, University of Nyíregyháza, Nyíregyháza, Hungary
| | - Tamás Kálai
- Faculty of Pharmacy, Institute of Organic and Medicinal Chemistry, University of Pécs, Pécs, Hungary
- János Szentágothai Research Center, University of Pécs, Pécs, Hungary
| |
Collapse
|